Anti-Angiogenic Therapy in Ophthalmology
This book provides a concise overview over the pathology of retinal angiogenic diseases and explains why anti-angiogenic therapy is effective in so many patients. The reader is guided through the various clinical indications for anti-angiogenic therapy an
- PDF / 8,258,551 Bytes
- 198 Pages / 504.63 x 737.01 pts Page_size
- 53 Downloads / 168 Views
Andreas Stahl Editor
AntiAngiogenic Therapy in Ophthalmology
Essentials in Ophthalmology
Series Editors Arun D. Singh
More information about this series at http://www.springer.com/series/5332
Andreas Stahl Editor
Anti-Angiogenic Therapy in Ophthalmology
Editor Andreas Stahl, MD Eye Center at the Medical Center University of Freiburg Freiburg, Germany
ISSN 1612-3212 ISSN 2196-890X (electronic) Essentials in Ophthalmology ISBN 978-3-319-24095-4 ISBN 978-3-319-24097-8 (eBook) DOI 10.1007/978-3-319-24097-8 Library of Congress Control Number: 2016937532 Springer Cham Heidelberg New York Dordrecht London © Springer International Publishing Switzerland 2016 This work is subject to copyright. All rights are reserved by the Publisher, whether the whole or part of the material is concerned, specifically the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfilms or in any other physical way, and transmission or information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed. The use of general descriptive names, registered names, trademarks, service marks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use. The publisher, the authors and the editors are safe to assume that the advice and information in this book are believed to be true and accurate at the date of publication. Neither the publisher nor the authors or the editors give a warranty, express or implied, with respect to the material contained herein or for any errors or omissions that may have been made. Printed on acid-free paper Springer International Publishing AG Switzerland is part of Springer Science+Business Media (www.springer.com)
Preface
In 2006, intraocular anti-VEGF therapy for exudative age-related macular degeneration (AMD) was ranked among the top 10 breakthroughs of the year by Science Magazine. Since then, antiangiogenic therapy has broadened its impact from AMD treatment to various other diseases of the eye like macular oedema in diabetic retinopathy or retinal vein occlusion. In other areas, for example, retinopathy of prematurity (ROP), antiangiogenic therapy is just beginning to find its place and is currently being evaluated in clinical studies that weigh its benefit against potential risks. As a third category, there are indications like macular telangiectasia where antiangiogenic therapy has after initial hopeful use become to be seen as potentially unfavourable in the long run. Due to the broad use of antiangiogenic therapies in these fundamentally different ocular diseases, it is crucial for the treating physician to understand both the underlying principles of angiogenic eye diseases and the available clinical data on therapies and outcome. This book therefore combines an overview over retinal vascular physiology with a detailed analysis of
Data Loading...
